Aurobindo Pharma Share Price
1652.50+15.20 (+0.93%)
+59.68% past 1 Year
Aurobindo Pharma is one of the leading vertically integrated formulations & API manufacturing companies in the world. It has a strong R&D focus and has a multi-product portfolio with manufacturing
Corporate filings & documents
Announcements
Submission of newspaper publication.
just nowSubmission of notice published in newspapers.
1 day agoSubmission of notice published in newspapers.
1 day agoIntimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited by Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
3 days agoIntimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited by Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
3 days agoSubmission of Press Release.
4 days agoSubmission of Press Release.
4 days agoIntimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
1 week agoIntimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
1 week agoSubmission of Voting Results and Scrutinizers Report of 39th AGM of the Company held on August 27 2026.
1 week agoSubmission of Voting Results and Scrutinizers Report of 39th AGM of the Company held on August 27 2026.
1 week agoSubmission of proceedings of 39th Annual General Meeting of the Company held on 27th August 2026.
1 week agoSubmission of proceedings of 39th Annual General Meeting of the Company held on 27th August 2026.
1 week agoIntimation of Participation in Investor/ Analyst meet held on September 1-2 2026 in Hong Kong
1 week agoIntimation of Participation in Investor/ Analyst meet held on September 1-2 2026 in Hong Kong
1 week agoIntimation of Investor/ Analyst meet scheduled on September 1 2026.
1 week agoIntimation of Investor/ Analyst meet scheduled on September 1 2026.
1 week agoIntimation of completion of US FDA inspection at Lannett Company LLC. a wholly owned subsidiary of Aurobindo Pharma USA Inc.
1 week agoIntimation of completion of US FDA inspection at Lannett Company LLC. a wholly owned subsidiary of Aurobindo Pharma USA Inc.
1 week agoIntimation of completion of US FDA inspection at Auro Peptides Limited a subsidiary of the Company.
2 weeks agoIntimation of completion of US FDA inspection at Auro Peptides Limited a subsidiary of the Company.
2 weeks agoIntimation of classification of US FDA inspection at Raleigh Plant North Carolina owned by Aurolife LLF a wholly owned step down subsidiary of the Company as Voluntary Actioin Indicated (VAI).
2 weeks agoIntimation of classification of US FDA inspection at Raleigh Plant North Carolina owned by Aurolife LLF a wholly owned step down subsidiary of the Company as Voluntary Actioin Indicated (VAI).
2 weeks agoIntimation of participation of officials of the Company in investors / analysts meet to be held on August 19 2026
3 weeks agoIntimation of participation of officials of the Company in investors / analysts meet to be held on August 19 2026
3 weeks agoIntimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited a wholly owned subsidiary of the Company.
3 weeks agoIntimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited a wholly owned subsidiary of the Company.
3 weeks agoSubmission of transcript of the earning call on the unaudited financial results for the quarter ended June 30 2026.
3 weeks agoSubmission of transcript of the earning call on the unaudited financial results for the quarter ended June 30 2026.
3 weeks agoIntimation of incorporation of a new wholly owned subsidiary.
3 weeks agoIntimation of incorporation of a new wholly owned subsidiary.
3 weeks agoSubmission of copies of notice published by the Company on August 7 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.
4 weeks agoSubmission of copies of notice published by the Company on August 7 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.
4 weeks agoSubmission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30 2026 as published in Business Standard and Nava Telangana on August 7 2026.
4 weeks agoSubmission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30 2026 as published in Business Standard and Nava Telangana on August 7 2026.
4 weeks agoIntimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13 2026 in Singapore & Hong Kong
4 weeks agoIntimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13 2026 in Singapore & Hong Kong
4 weeks agoIntimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.
4 weeks agoIntimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.
4 weeks agoSubmission of Press Release on financial results of the Company for the first quarter ended June 30 2026.
4 weeks agoSubmission of Press Release on financial results of the Company for the first quarter ended June 30 2026.
4 weeks agoSubmission of investor presentation.
4 weeks agoSubmission of investor presentation.
4 weeks agoThe Board of Directors of the Company at its meeting held today August 5 2026 has inter alia considered and approved:a) the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. b) a proposal to file a Scheme of Amalgamation for merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited wholly owned step-down subsidiaries of the Company with Eugia Pharma Specialities Limited a wholly owned subsidiary of the Company with Honble NCLT Hyderabad that has been approved by the Board of Directors of the respective companies and also the Company.
4 weeks agoThe Board of Directors of the Company at its meeting held today August 5 2026 has inter alia considered and approved:a) the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. b) a proposal to file a Scheme of Amalgamation for merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited wholly owned step-down subsidiaries of the Company with Eugia Pharma Specialities Limited a wholly owned subsidiary of the Company with Honble NCLT Hyderabad that has been approved by the Board of Directors of the respective companies and also the Company.
4 weeks agoSubmission of copies of notice published in newspapers.
1 month agoSubmission of copies of notice published in newspapers.
1 month agoConfirmation of dispatch of letter to the shareholders who have not registered their email ids providing weblink for integrated Annual Report 2025-26.
1 month agoConfirmation of dispatch of letter to the shareholders who have not registered their email ids providing weblink for integrated Annual Report 2025-26.
1 month agoSubmission of BRSR for FY 2025-26.
1 month agoConcalls & investor presentations
Aug 2026
ConcallPresentation
Aug 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Nov 2025
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Nov 2024
ConcallPresentation
Nov 2024
ConcallPresentation
Aug 2024
ConcallPresentation
Aug 2024
ConcallPresentation
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Nov 2023
ConcallPresentation
Nov 2023
ConcallPresentation
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Jan 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
Feb 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2025-08-08
Dividend
4.0
2024-02-20
Dividend
1.5
2023-11-20
Dividend
3.0
2023-02-17
Dividend
3.0
2022-06-06
Dividend
4.5
2022-02-18
Dividend
1.5
2021-11-17
Dividend
1.5
2021-08-27
Dividend
1.5
2021-02-22
Dividend
1.5
2020-11-23
Dividend
1.25
2020-08-21
Dividend
1.25
2020-02-17
Dividend
1.75
2019-11-21
Dividend
1.25
2019-02-15
Dividend
1.25
2018-11-20
Dividend
1.25
2018-02-20
Dividend
1.0
2017-11-21
Dividend
1.5
2017-06-08
Dividend
1.25
2016-11-24
Dividend
1.25
2016-06-09
Dividend
0.7
2016-02-18
Dividend
0.7
2015-11-19
Dividend
0.6
2015-08-21
Dividend
0.5
2015-07-20
Bonus
1:1
2015-06-08
Dividend
1.0
2015-02-16
Dividend
2.0
2014-08-13
Dividend
1.5
2014-06-11
Dividend
1.75
2013-11-19
Dividend
1.25
2013-07-30
Dividend
0.5
2013-02-18
Dividend
1.0
2012-07-30
Dividend
1.0
2011-07-20
Dividend
1.0
2011-02-10
Split
5:1
2010-11-11
Dividend
5.0
2010-09-13
Dividend
2.0
Company details
Registered office
Plot No. 2 Maitrivihar Ameerpet Hyderabad Telangana PIN: 500038 Tel No: 040-23736370 / 23747340 Fax No: 040-23741080 / 23746833 Email: [email protected] Internet: www.aurobindo.com
Registrars
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com
Management
Mangalam Ramasubramanian Kumar, Chairman
K Nityananda Reddy, Vice Chairman & Managing Director
M Madan Mohan Reddy, Whole Time Director
Santanu Mukherjee, Non Executive Independent Director
Girish Paman Vanvari, Non Executive Independent Director
Punita Kumar Sinha, Non Executive Independent Director
P Sarath Chandra Reddy, Non Independent & Non Executive Director
PV Ramprasad Reddy, Promoter & Non-Executive Director
Satakarni Makkapati, Non Independent & Non Executive Director
B Adi Reddy, Company Secretary & Compliance Officer
Details
BSE 524804
NSE AUROPHARMA
ISIN INE406A01037